LB Pharmaceuticals Inc Common Stock
LBRX
$42.69
Updated: 23/09/2026, 00:06:03
Market Cap
$1.22B
Sector
Healthcare
Industry
Biotechnology
Country
US
Stock valuation chart
One-year closing share-price history for LBRX
Company Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
USD
NASDAQ
CEO: Heather D. Turner
Employees: 49
Asset Summaries
Latest generated summaries for LBRX
No summaries found.
Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for LBRX.
- Share price
- $42.69
- Market cap
- $1.22B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Heather D. Turner
- Employees
- 49
- IPO date
- 11/09/2025
- Beta
- 0.42340934
- Last dividend
- $0.00
- Day range
- $41.21 – $43.40
- 52-week range
- $13.36 – $50.16
- 1-day performance
- -0.70%
- 1-year performance
- 219.54%
- Current drawdown (1Y)
- -14.89%
- CIK
- 0001691082
- CUSIP
- 50180M108
- ISIN
- US50180M1080
- Created
- 07/12/2025, 05:01:13
- Last update
- 23/09/2026, 00:06:03
Track LB Pharmaceuticals Inc Common Stock with an AI analyst
See which prediction-market events move LBRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Latest Database News
News linked to LBRX from your Railway `news_articles` table.